Date |
2019- 2019 |
Company or interest group |
DOC |
Value |
Less than EUR 1,000 |
Payment made to |
Personal account |
Date |
2018- 2018 |
Company or interest group |
ROCHE |
Value |
EUR 1,000-10,000 |
Payment made to |
Personal account |
Date |
2019- 2019 |
Company or interest group |
astellas |
Value |
EUR 1,000-10,000 |
Payment made to |
Personal account |
Date |
2018- 2018 |
Company or interest group |
on behalf of VIFOR PHARMA |
Value |
EUR 1,000-10,000 |
Payment made to |
Personal account |
Date |
2018- 2019 |
Company or interest group |
retrophin |
Value |
EUR 1,000-10,000 |
Payment made to |
Personal account |
Nature of interest |
national leader PROTECT study |
Nature of restriction |
Unrestricted |
Date |
2019- 2019 |
Company or interest group |
GSK |
Value |
Less than EUR 1,000 |
Payment made to |
Personal account |
Nature of interest |
national leader ASCEND ND study |
Nature of restriction |
Unrestricted |
Date |
2019- 2019 |
Company or interest group |
astellas |
Value |
EUR 1,000-10,000 |
Payment made to |
Personal account |
Nature of interest |
advisory board |
Date |
2018- 2018 |
Company or interest group |
DOC |
Value |
EUR 1,000-10,000 |
Payment made to |
Personal account |
Nature of interest |
Advisory board |